Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

12 Months Ended

Dec. 31, 2022

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

18.

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2022, 2021 and 2020 (in thousands, except share and per share amounts):


	Year Ended December 31,
	2022			2021			2020
Net loss attributable to Adaptive Biotechnologies Corporation	$	(200,191	)	$	(207,279	)	$	(146,227	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		142,515,917			140,354,915			131,216,468
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(1.40	)	$	(1.48	)	$	(1.11	)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2022, 2021 and 2020, as they had an anti-dilutive effect:


	Year Ended December 31,
	2022		2021		2020
Stock options outstanding		13,892,287		13,097,374		16,125,548
Nonvested restricted stock units outstanding		4,799,850		693,173		38,125
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		410,282		—		—
Common stock warrant outstanding		—		8,570		56,875
Total		19,102,419		13,799,117		16,220,548